Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 718-723

  Shiotsu, Yayoi ^a   Mori, Yasukiyo ^a   Nishimura, Masato ^b   Sakoda, Chikako ^b   Tokoro, Toshiko ^b   Hatta, Tsuguru ^c   Maki, Noboru ^d   Iida, Kumiko ^d   Iwamoto, Noriyuki ^b   Ono, Toshihiko ^b   Matsuoka, Eiko ^a   Kishimoto, Noriko ^a   Tamagaki, Keiichi ^a   Matsubara, Hiroaki ^a   Kosaki, Atsushi ^e  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Urology Division   (Japan)

^c Omihachiman Community Medical Center   (Japan)

^d FUJIREBIO INC   (Japan)

^e KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; S100A12 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; STROKE;

AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; S100 PROTEINS;

EID: 79955566808     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08310910     Document Type: Article

References (30)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
2. Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325: 163-167, 2003
3. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521, 2008
4. Kendrick J, Chonchol MB: Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 4: 672-681, 2008
5. Hou FF, Ren H, Owen WF Jr., Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X: Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15: 1889-1896, 2004
6. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT: RAGE (Receptor for Advanced Glycation Endproducts), RAGE li-gands, and their role in cancer and inflammation. J Transl Med 7: 17, 2009
7. Thornalley PJ, Rabbani N: Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 22: 400-404, 2009
8. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypep-tides. Cell 97: 889-901, 1999
9. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668, 2001
10. Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB: Multiple structural states of S100A12: A key to its functional diversity. Microsc Res Tech 60: 581-592, 2003
11. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL: Proinflammatory properties of the human S100 protein S100A12. J Leukocyte Biol 69: 986-994, 2001
12. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T: Increased plasma S100A12 (ENRAGE) levels in patients with type 2 diabetes. J Clin Endocri-nol Metab 89: 5423-5428, 2004
13. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Na-kajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H: Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 29: 18-24, 2009
14. Pietzsch J, Hoppmann S: Human S100A12: A novel key player in inflammation? Amino Acids 36: 381-389, 2009
15. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340: 115-126, 1999
16. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19: 53-61, 2001
17. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial 15: 329-337, 2002
18. Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE, Powe NR, Coresh J, Klag MJ: The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 74: 1335-1342, 2008
19. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE: The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53: 2129-2140, 2009
20. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J: S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361: 1270-1272, 2003
21. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J: Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 42: 1383-1389, 2003
22. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J: Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52: 847-853, 2003
23. Uchiyama-Tanaka Y,Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, Matsubara H: Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 12: 28-32, 2008
24. Koyama H, Shoji T, Fukumoto S, Shinohara K, Shoji T, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, Yamamoto H, Nishizawa Y: Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27: 147-153, 2007
25. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91: 4628-4634, 2006
26. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R: Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 11: R39, 2009
27. Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, Hsu K, Rahimi F, Di Girolamo N, Song C, Jessup W, Kockx M, Bo-bryshev YV, Freedman SB, Geczy CL: Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol 183: 593-603, 2009
28. Mahajan N, Malik N, Bahl A, Dhawan V: Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 207: 597-602, 2009
29. Hoffmann Bowman M, Wilk J, Heydemann A, Kim G, Reh-man J, Lodato JA, Raman J, McNally EM: S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 106: 145-154, 2009
30. Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, Oki-gaki M, Masaki H, Toyoda N, Inoue-Shibata M, Kimura Y, Nishikawa M, Iwasaka T: The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 171: 211-218, 2003